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I NTRO D U CTI 0 N 
Antimicrobial resistance amongst respiratory tract 
pathogens has become an increasing problem world- 
wide during the last 15 years. Penicillin-resistant strains 
of the three most common pathogens, Streptococcus 
pneumoniae, Haemophilus infuenzae and Moraxella catar- 
rhalis, are being isolated with increasing frequency in 
many countries, with incidence rates of over 25% in 
many cases. Similar rates are also found for macrolide 
resistance in Streptococcus pneurnoniae. Therefore, the 
clinical efficacy of the main groups of antibiotics 
used in the conventional therapy of respiratory tract 
infections may be compromised in the future. These 
trends have fueled the development of new fluoro- 
quinolones with improved activity against respiratory 
pathogens. The introduction of this group of anti- 
microbial agents may help to alleviate the situation, 
assuring an effective treatment in resistant cases. This 
paper reviews some of the current trends in, and 
thinking about, the epidemiology of resistance among 
respiratory tract pathogens, and some of the mech- 
anisms of resistance, and considers the potential role of 
the newer fluoroquinolones in treatment. 
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EPIDEMIOLOGY OF RESISTANCE 
Streptococcus pneumoniae 
Until the 1970s, Streptococcuspneurnoniae infections were 
successfully treated with p-lactam antibiotics. Since 
then, however, increasing resistance to penicillin has 
been reported on a worldwide scale, with 10-50% 
of Streptococcus pneumoniae isolates now being non- 
susceptible to penicillin [ 11. High-level penicillin 
resistance in Streptococcus pneumoniae is defined as an 
MIC > 1 mg/L, intermediate penicillin resistance as an 
MIC of 0.12-1 mg/L and susceptibility as an MIC 
<0.12 mg/L. Figure 1 shows the current situation 
regarding resistance to penicdlin (MIC B0.12 mg/L) 
among Streptococcus pneumoniae strains around the world. 
The data were collected &om approximately 200 centers, 
mainly between 1993 and 1997 (Baquero, unpublished 
data). In western Europe, the high rates of resistance 
found in the early 1990s in Spain (about 35%) are now 
also found in France, and rates have started to increase 
in Portugal (20%). Italy and Greece initially had very 
low rates (5-lo%), but these have also been increasing 
during the last few years. A small number of resistant 
strains have also been observed in the UK. Resistance 
remains relatively low in other European countries, 
such as Switzerland, Germany, the Czech Republic, 
Belgium, The Netherlands and Scandinavian countries, 
with incidence rates of 3-10%. In eastern Europe, high 
rates of resistance, exceeding 25-30%, are found in 
Slovakia, Hungary, Rumania, Bulgaria and Turkey. 
Overall resistance to penicillin in Europe is approxi- 
mately 23% (range 6-54%), with the highest prevalence 
in Madrid, Barcelona and Toulouse and many centers 
reporting resistance rates greater than 15% [2]. 
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Figure 1 Worldwide frequency of isolation of penicillin-resistant pneumococci (MIC >0.12 mg/L: intermediate and high- 
level penicillin-resistant strains). 
In general, in North African countries, such as 
Tunisia, Morocco and Egypt, there is much less 
resistance than in Europe, with rates below 10%. In 
both western, eastern and southern African countries, 
the prevalence of resistance may be much higher, 
ranging from 10% to 40%, with the highest rates in 
South Africa, Kenya and Nigeria. Israel and Saudi 
Arabia have also reported high rates of resistance of 
around 20-30%. An important focus of penicillin 
resistance, with rates exceeding 40%, occurs in the Far 
East, including Japan and Korea, with slightly lower 
rates in Indonesia and New Guinea. Singapore, the 
Philippines and Australia have rates of 10-20%, while 
in New Zealand the rate is less than 10%. In North 
America, the rates are around 30% in the USA and 
5-15'36 in Mexico and Canada. In South America, rates 
of 20-2596 are found in Argentina, Chile, Brazil and 
Venezuela, with lower rates (5515%) in Colombia, 
Ecuador and Peru. 
The maximum levels of penicillin resistance which 
have been reported in Streptococcus pneumoniae are 
8 mg/L in France and 16 mg/L in Hungary [3]. 
Penicillin-resistant Streptococcus pneumoniae strains are 
more frequently isolated from children who are 
hospitalized, are in day-care centers, or have been 
previously exposed to antibiotics (particularly those 
with acute otitis media), or in AIDS patients. These 
factors may explain some local discrepancies where 
very high incidences of penicillin-resistant strains occur 
in some centers and low incidences in others in the 
same geographic area. 
Penicillin-resistant strains are also resistant to other 
0-lactam antibiotics such as ampicillin, amoxycillin, 
amoxycillin/clavulanic acid and oral cephalosporins. 
All cephalosporins are less active than penicillin or 
amoxycillin against intermediate and resistant strains. 
Of the oral cephalosporins. cefaclor, cefixime and 
loracarbef are among the least active drugs against 
penicillin-intermediate pneumococci; cefuroxime, 
cefpodoxime, cefdinir remain the most active agents 
under in vitro conditions. In addition, in many countries, 
the majority or all of these strains are also cross-resistant 
to trimethoprim/sulfamethoxazole. Another concern 
in Streptococcus pnenmoniae is resistance to niacrolides, 
which is often found in penicillin non-susceptible 
strains. Current levels of niacrolide resistance are in the 
order of 3-1 0% in penicillin-susceptible strains and 
30-40% in penicillin non-susceptible strains, but as 
with other resistance rates, this varies widely from 
country to country and anecdotal evidence from 
France indicates that it could be as high as 60%. Thus, 
a niajor problem is the emergence of multiply-resistant 
strains of Streptococcus przeumoniae. 
In Europe, the lowest rates of macrolide resistance 
in Streptococcus pneumonine (< 5% erythromycin resist- 
ance) are found in Switzerland, Germany, Turkey, 
Sweden, Greece and the UK. In Spain the rate 
increased from < I %  in 1979 to 5.5% in 1988 and is 
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now approximately 17%. In France, Belgium, Italy 
and Hungary the rate is about 25%, and in Finland 
it is about 15%. In the USA rates have reached 25-30%, 
but they are lower (10-20%) in Mexico, and very low 
(below 10%) in Canada, Argentina, Chile, Uruguay, 
and Brazil. Extremely high rates of resistance, 
exceeding 40%, are found in Japan and Korea. 
A high correlation can be established in many 
countries between the local prevalence of penicillin 
resistance and macrolide resistance. This suggests that a 
relatively low number of clones with evolving penicillin 
resistance have also acquired macrolide resistance deter- 
minants. For example, in Spain the rate of macrolide 
resistance in penicillin-susceptible strains is around 5%, 
but the rate increases to nearly 20% in intermediately 
resistant pneumococci and to 25% in high-level resistant 
strains. This may indicate that high-level resistance 
has evolved on certain intermediately resistant clones 
which harbored macrolide resistance determinants. 
Since different clones are involved in different types of 
infection, this may also explain why the rates of both 
penicillin and macrolide resistance tend to be signi- 
ficantly higher in isolates obtained from middle ear 
effusion or sputum than in blood isolates. 
Haemophilus influenzae 
The production of p-lactamase is a widespread problem 
in H. infuenzae, with incidence rates of 10-40% for 
P-lactamase-producing strains in many countries. These 
strains may also have a decreased susceptibility to 
cephalosporins, particularly to cefaclor (MIC 32 mg/L) 
and cefalexin, and appproximately 10% are also resistant 
to trimethoprim/suKamethoxazole (MIC 2 4 mg/L). 
The prevalence of P-lactamase production varies among 
different European countries. The highest rates, of 
around 35% but exceeding 50% of the isolates in some 
reports, are found in Spain [4,5]. Slightly lower rates are 
found in France, ranging from 25% to 35%, the UK 
(20%), Ireland (17%), Belgium (15%), Portugal (12%), 
Finland (1 2%), Sweden (1 0%) , Denmark (9%), 
Germany (7%), The Netherlands (7%) and Italy (5%) 
[7-91. Figure 2 shows the incidence of p-lactamase- 
positive H. infuenzae strains in Europe. In the USA, 
according to the Alexander Project data, the rate was 
20-38% in 1992-93 [4] and around 35% in 1995 (un- 
published results). A similar rate of 36% was reported 
by Doern et al from a 1994-95 survey [5]. 
A potential new problem in H .  influenzae is the 
possible development of resistance to the p-lactamase 
inhibitors clavulanate and sulbactam, used in combina- 
tion with aminopenicillins, which occurs at a pre- 
valence of about 1% in some countries such as the USA 
(see page 2S23) [5]. The evolution of p-lactamase- 
negative, ampicillin-resistant strains is a concern in 
many countries, although the incidence of these strains 
seems to have stabilized at around 4% at the present 
time. In particular patients, such as cystic fibrosis 
patients with chronic lung infection, the incidence may 
reach 10% of all H. influenzae isolates (R. Cant6n and 
E Baquero, unpublished data). Most of these strains 
have relatively low-level resistance to aminopenicillins 
and a very high MIC to cefaclor and other cephalo- 
sporins [5]. Resistance to cefotaxime and ceftriaxone 
has not been reported hitherto but, nevertheless, 
surveillance should be carried out to investigate this 
in more detail (see below). Acquired resistance to 
macrolides in H .  infuenzae is probably non-existent 
because macrolides do not have any significant activity 
against this bacterium and therefore there is no 
potential for exerting a selective effect on potential 
resistant variants [6]. 
Moraxella catarrhah 
Prior to the mid-l970s, M. catarrhalis was considered 
to be non-P-lactamase-producing, but since then 
P-lactamase-positive strains have spread worldwide. 
Resistant M .  catarrhalis strains produce the closely 
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Figure 2 Incidences of P-lactamase-positive H. influenrue 
strains in Europe. 
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related p-lactamases BRO-1, BRO-2 and BRO-3, 
which are apparently distinct from TEM and other 
p-lactamases [7]. These p-lactamase genes appear to 
be chromosomally located, possibly on a conjugative 
transposon, although transfer of p-lactamase and 
the presence of plasmids have been reported [7-91. 
p-Lactamase-producing strains are resistant to penican, 
amoxycillin (MIC 16-64 mg/L) and ampicillin, and 
have diminished susceptibility to several cephalosporins 
(cefuroxime MIC 16-128 mg/L). Resistance rates for 
1992-93 were reported by the Alexander Project to 
have increased significantly in Europe from 70% in 
1992 to 82% in 1993, and also increased, although not 
significantly, in the USA from 85% to 92% [lo]. N o  
significant high-level resistance to macrolides has been 
found in most surveys, but low-level resistance has 
been described at low incidence rates in Spain (Emilio 
Bouza, personal communication). Additionally, no 
significant resistance to fluoroquinolones has been 
found [lo]. 
MECHANISMS OF RESISTANCE 
0-Lactam resistance in Streptococcus pneumoniae 
In Streptococcus pneumoniae, p-lactam resistance is due 
to the alteration of the antibiotic molecular targets, 
the penicillin-binding proteins (PBPs), involved in the 
biosynthesis of the cell wall. Inhibition of bacterial 
growth and eventually cell lysis are the consequences of 
the 0-lactam binding to some of these proteins. Small 
changes in the sequences of the genes encoding 
essential PBPs, originating from spontaneous mutation, 
may be sufficient to decrease the susceptibility of 
Streptococcus pneumoniae to certain p-lactams. This event 
is rare in the case of penicillins but more frequent in 
the case of cephalosporins. Nevertheless, the most 
common mechanism of acquiring p-lactam resistance 
is the incorporation into the genomes of susceptible 
organisms (by homologous recombination) of pieces 
of ‘resistant PBPs’ originating in other streptococci, 
particularly Streptococcus mitis or Streptococcus oralis. 
Streptococcus pneumoniae is able to acquire foreign 
DNA by transformation under particular conditions, 
known as conditions for competence (competence 
to be transformed). One of these conditions is a cell 
density of about 107/mL (the ‘quorum’ density), at 
which both DNA release and uptake are increased. This 
is a temporary phenomenon which appears to be 
regulated by a pheromone. competence-stimulating 
peptide (CSP) [ I l l .  The acquisition of pieces of 
resistant PBPs results in the formation of mosaic PBPs 
[ 121. Typically, the genetic divergence among the 
‘resistant fragments’ of DNA and the DNA encoding 
the resident PBPs is around 20%. The natural mismatch 
repair system in Streptococcus pneumoniae (hex gene) 
seems not to be a major obstacle for interspecific 
recombination, as the system is probably prone to 
saturation at low levels of genetic divergence [ 131. 
In the future, the possibility of a ‘mutator pheno- 
type’ in Streptococcus pneumoniae should be urgently 
explored. This particular phenotype tends to occur as 
a consequence of damage to the DNA repair system, 
which increases the possibility of multiple mutations, 
even in an individual cell. This phenotype may arise 
under conditions of biological stress, increasing the 
ability of the cell to adapt rapidly to antibiotic pressure. 
Interestingly, the acquisition of single-strand DNA by 
transformation may increase the rate of mutation, so 
that both these phenomena may together explain the 
rapid increase of p-lactam resistance in Streptococcus 
pneumoniae (F. Baquero, personal communication). 
Mutations in PBP2x of Streptococcus pneumoniae 
are essential for the development of resistance to 
cephalosporins [ 14,151. Cefotaxime challenge leads to 
the selection of cefotaxime-resistant PBP2x mutants, 
but these variants only marginally reduce the suscepti- 
bility to penicillins, with the possible exception of 
oxacillin. O n  the contrary, mutations in PBP2b are 
essential for the development of high-level penicillin 
resistance, and these mutations arise after challenge 
with penicillins [16.17]. Some PBP mutations may 
favour the incorporation of foreign DNA, and there- 
fore may be involved in the early stages of penicillin 
resistance. Mutations in PBPla may also contribute to 
the development of high-level resistance to penicillins, 
and, in fact, highly resistant strains may have a 
combination of mutated PBPs [18]. Mutations in PBP3 
may result in a very modest increase in resistance to 
penicillins and cephalosporins. Interestingly, this PBP3 
is probably a target for clavulanic acid, and the 
interaction with this drug may result in a bacterial cell 
more prone to cell lysis but the practical consequences 
of this observation remain to be explored [19]. 
Low-level, non-PBP-related p-lactam resistance 
has recently been shown in Streptococcus pneumoniae. 
involving the ciaH (hstidine-kinase) and cpoA (glycosyl- 
transferase) genes, and other undescribed genes [20,21]. 
Mutations in the ciaH gene suggest that signal trans- 
duction systems may play a role in the expression of 
silent genes involved in 0-lactam resistance. 
The fact that Streptococcus pneumoniae has not 
evolved P-lactani resistance by acquisition of p- 
lactamases poses an interesting question. Theoretically, 
there is a certain availability of plasmids encoding 
p-lactamases in other Gram-positive genera such as 
Staphylococcus or Enterococcus. Unpublished preliminary 
results indicate that the fitness of Streptococcus in the 
presence of P-lactamase is severely damaged (E Baquero). 
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P-Lactam resistance in Haemophilus influenzae 
In H. infuenzae, there are three possible mechanisms of 
resistance to penicillins: alteration of PBPs; inactivation 
of the drug by p-lactamases; and, although not fully 
demonstrated, reduction of penicillin permeability 
into the cell (efflux mechanisms). Of  these, cleavage 
of the 0-lactam ring to produce inactive penicillionic 
acid derivatives by the production of bacterial p- 
lactamases is the most common and the most clinically 
relevant. 
Bacterial resistance mediated by p-lactamases 
is now widespread in H. infuenzae and is the most 
important mechanism for bacterial resistance to p- 
lactam antibiotics [22]. The most prevalent p-lactamase 
is TEM-1, the same widespread enzyme found in 
ampicillin-resistant Escherichia coli (perhaps with neutral 
Val-83 and His-96 mutations), but other enzymes, with 
a similar spectrum of activity, such as ROB-1 and VAT- 
1, are also involved. p-Lactamase-positive strains are 
not susceptible to aminopenicillins and show a reduced 
susceptibility to cefaclor, but, in general, remain 
susceptible to the combination of a p-lactam and 
P-lactamase inhibitor and to the third-generation 
cephalosporins. 
Nevertheless, H. infuenzae strains with decreased 
suceptibility to p-lactam and p-lactamase inhibitor 
combinations are one of the emerging problems in 
the antibiotic treatment of respiratory tract infections. 
Doern et a1 reported an incidence of 1% for these 
strains among clinical isolates in the USA in a recent 
survey [5]. The typical phenotype of these strains is 
characterized by MICs of amoxycillin ranging from 
8 to 32 mg/L, MICs of cefaclor ranging from 4 to 
64 mg/L, but full susceptibility to third-generation 
cephalosporins. With such a high frequency of 
P-lactamase-producing strains, there is the potential for 
point mutation evolution to produce an extended- 
spectrum 0-lactamase that is also active against third- 
generation cephalosporins, or resistant to the inhibition 
by 0-lactamase inhibitors, as has occurred in Entero- 
bacteriaceae. Close surveillance of small increases in 
MIC levels of third-generation cephalosporins, possibly 
using ceftazidime as a marker, is urgently required. 
The classic group of P-lactamase-negative, ampi- 
cillin-resistant strains is found in Europe at an incidence 
of 2.5%. Resistance is due to PBP changes in most cases 
and these strains have high-level resistance to cefaclor 
(generally MIC >32 mg/L) and other oral cephalo- 
sporins and also reduced susceptibility to p-lactam and 
p-lactamase inhibitor combinations [6,23]. 
P-Lactam resistance in Moraxella catarrhalis 
A very high percentage of M. catarrhalis strains are p- 
lactamase producers, and, in general, the 0-lactamases 
involved are BRO-1 and BRO-2. While they exhibit 
resistance to agents such as penicillin, ampicillin and 
amoxycillin, they remain susceptible to p-lactam and 
P-lactamase inhibitor combinations, e.g. amoxycillid 
clavulanic acid, and trimethoprim/sulfamethoxazole. 
There is no evidence to indicate there will be any 
change in the susceptibility to these alternative anti- 
microbials in the near future [6,8]. 
Macrolide resistance in Streptococcus pneumoniae 
In Streptococcus pneumoniae, an M phenotype, which 
confers resistance to macrolides but susceptibility to 
lincosamide and streptogramin B antibiotics, has been 
described in some strains 124,251. The determinant for 
this phenotype appears to be different from known erm 
genes and is not mediated through target modification. 
Sutcliffe et a1 have described an efflux system for 
erythromycin in these M strains which is apparently 
distinct from the efflux system in staphylococci [24]. 
The phenotype characterized by low-level erythro- 
mycin resistance (MICs ranging from 0.25 to 8 mg/L), 
with cross-resistance to 14- and 15-membered macro- 
lides but susceptibility to lincosamides (clindamycin) 
and streptogramin B, is found in Spain at a rate of about 
5%. This phenotype is frequently due to the presence 
of the efflux system, but in some cases may be related 
to inducible expression of an erm gene. 
Fluoroquinolone resistance in Streptococcus pneumoniae 
In Gram-negative bacteria, alterations ingyrA, encodmg 
for the A subunit of DNA gyrase (topoisomerase II), 
are the most common cause of resistance to fluoro- 
quinolones, with high-level resistance due to two or 
more mutations in this gene 1261. Alterations in the 
subunits of topoisomerase IV may also lead to decreased 
fluoroquinolone activity. In general, resistance will 
appear first in the gene encoding the most sensitive 
drug target. In Streptococcus pneumoniae, the primary 
targets for most fluoroquinolones tested so far are parC 
and parE, which encode for the two subunits of 
topoisomerase IV, with gyrA as the secondary target 
[27]. No mutations in gyrA are found in Streptococcus 
pneumoniae strains with a ciprofloxacin MIC of 8 mg/L, 
but changes are found in Ser-89 to Tyr or Phe, or 
Asp-83 to Gly in ParC, or Asp-435 to Asn in ParE. In 
high-level resistant strains, with a ciprofloxacin MIC 
>32 mg/L, gyrA mutations are added, typically Ser-84 
to Tyr or Phe, or Glu-88 to Lys [28-311. 
Fluoroquinolone resistance in Haemophilus influenzae 
Resistance to fluoroquinolones is also emerging in 
H .  infuenzae. Current rates of resistance to cipro- 
floxacin in H. infuenzae are about 0.4%. Strains 
requiring ciprofloxacin 2 mg/L for inhibition have 
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been recently isolated from adult cystic fibrosis patients 
[32]. In two of these cases, the same strain (identical 
PFGE profile) was isolated during periods of time of 
15-17 months, suggesting that ciprofloxacin resistance 
may have a small biological cost for the mutated strain. 
Normal susceptible strains are inhibited by ciprofloxacin 
concentrations of 0.06 mg/L. Any strain with higher 
MICs should be considered as potentially harboring 
topoisomerase mutations. As Georgiou et a1 have 
pointed out, the mutation leading to an Asp-88 to Tyr 
replacement in the DNA gyrase (GyrA) may produce 
a ciprofloxacin MIC of 0.12 mg/L; Asp-88 to Asn in 
GyrA plus Ser-84 to Ile mutations in topoisomerase IV 
(ParC) lead to MICs of 2 mg/L; and triple mutations, 
a Ser-84 to Tyr and Asp-88 to Asn in GyrA, plus Glu- 
88 to Lys in ParC, may lead to MICs of 32 mg/L [33]. 
Potential new mechanisms of resistance which could 
occur are an acr efflux mechanism similar to that 
found in Escherichia coli and a marA-like mechanism of 
decreased permeability. 
The natural history of fluoroquinolone resistance 
in H .  infuenzae may be as follows: (1) primary selection 
ofgyrA single mutants, with a very low increase in the 
MIC of ciprofloxacin (these strains may be detectable 
by nalidixic acid resistance); (2) secondary selection of 
parC mutants, with ciprofloxacin MICs ranging from 
2 to 16 mg/L; (3) tertiary selection of newgyrA mutants, 
with high ciprofloxacin MICs of 32 mg/L. Thus, GyrA 
is probably the primary target of fluoroquinolones 
(ciprofloxacin) and amino acid changes in this protein 
are probably required before ParC mutations can 
influence resistance levels. The potential spread of 
fluoroquinolone resistance in clinical practice may 
depend on the ability of resistance genes to spread 
among bacterial populations or on the selection and 
spread of particular resistant clones. The transformation 
frequency in H. infuenzae ranges from to but 
despite these high rates for potential DNA exchange 
the population genetic analysis of H. inzuenzae type B 
has revealed a very clonal population structure, and 
similar results have been found in multiresistant non- 
typeable strains [34,35]. 
Recent evidence 
In very high-level resistance (MIC 128 mg/L), other 
mechanisms may be involved. It is probable that an 
efflux mechanism exists for fluoroquinolones which 
may be driven by ATE and this should be investigated 
in more detail. Certain strains can be selected which 
have very high ciprofloxacin resistance (MIC 128 mg/L), 
although this concentration is considered to be un- 
attainable after conventional treatment. It can be 
suggested that lysis of host cells which accumulate the 
drug or lysis of the bacterial cells may provoke a local 
release of high quantities of ciprofloxacin. 
For some fluoroquinolones, such as sparfloxacin, 
the primary target may be GyrA, not ParC. Stepwise 
sparfloxacin selection yields GyrA mutants, typically in 
Ser-83, and only ParC mutants in a secondary step, and 
sparfloxacin-resistant strains may remain ciprofloxacin 
susceptible [36]. This observation suggests the possi- 
bility of future fluoroquinolone-fluoroquinolone com- 
binations that will act simultaneously on a double 
target. O f  interest for the newer fluoroquinolones, 
including levofloxacin, is the possibility of suppressing 
the first single-step parC mutations in Streptococcus 
pneumoniae. ParC is probably the first protein involved 
in Streptococcus pneumoniae in the targeting of fluoro- 
quinolones which is modified to confer resistance. If it 
is possible to suppress the primary mutant parC by using 
the newer fluoroquinolones that remain very active 
against these mutants, then the double mutant and 
high-level resistance may be prevented [36-381. In 
contrast, the widespread use of older fluoroquinolones 
such as ciprofloxacin could eventually increase the 
reservoir of mutated parC genes, decreasing the 
potential efficacy ofboth old and new compounds [27]. 
For the early detection of resistance to fluoro- 
quinolones, the use of nalidixic acid, to detect primary 
mutations, plus ciprofloxacin to detect secondary 
mutations would be useful as markers in H. infuenzae. 
In Streptococcus pneumoniae, ofloxacin or levofloxacin 
plus sparfloxacin should be tested simultaneously to 
observe differences in MICs between the newer 
fluoroquinolones and identify possible differences in 
the primary target. In future, more in vitro research 
is needed to identify the phenotype of primary mutants 
and the exact MIC for the different drugs of these 
mutants. These results would then enable the associa- 
tion of certain MICs with strains harboring a given 
mutation. 
Older fluoroquinolones, such as ciprofloxacin, may 
ampli@ the mutant gene pool for primary mutations, 
i.e. in the parC genes in Streptococcus pneumoniae. Thus, 
the use of these fluoroquinolones in general, and in 
respiratory tract infections in particular, may increase 
the likelihood of resistance emerging. In contrast, the 
newer fluoroquinolones may suppress the first mutant 
by having a more balanced activity on both parC and 
gyrA. Preventing both mutations at the same time 
may slow down the emergence of resistance, and 
the development of double mutants could possibly 
be prevented. This would explain the relatively low 
mutation rate with the newer fluoroquinolones where 
both targets may be inhibited simultaneously. However, 
diversification of fluoroquinolones could enrich all 
resistant gene pools by cross-transformation between 
B a q u e r o  e t  al:  E p i d e m i o l o g y  a n d  m e c h a n i s m s  o f  r e s i s t a n c e  2 S 2 5  
purC and gyrA mutants leading to double mutants and 
high-level resistance strains. 
It seems evident that one of the potential advan- 
tages of the use of the newer fluoroquinolones could 
be to decrease or counterbalance the spread of resistance 
to other antimicrobial agents by helping to diversify the 
number of treatments available and thereby reduce 
the selective pressure on any one antibiotic group. To 
prevent the spread of resistance to fluoroquinolones, 
the essential message is that blood, tissue and mucosal 
fluoroquinolone levels should be greater than the 
MIC of that agent for single primary mutants. Animal 
models and careful human observations, including 
normal oropharyngeal flora, are needed to show 
whether this is the case. 
Finally, the increasing use of fluoroquinolones in 
respiratory tract infections and the impact that this may 
have on non-respiratory pathogens must be considered. 
Large-scale use of fluoroquinolones, as with other classes 
of antibiotics, has the potential to produce resistance in 
non-respiratory pathogens. Essentially, therefore, it is 
important that, as with any other groups of antibiotics, 
the newer fluoroquinolones are used appropriately and 
‘target’ groups of patients, considered most suitable for 
therapy, identified. 
CONCLUSIONS 
Resistance to common antimicrobial agents used in 
respiratory tract infections is a continuing problem with 
both community- and hospital-acquired pathogens. An 
increasing problem is the emergence and potential 
worldwide spread of high-level p-lactam resistance 
among Streptococcus pneumoniae and H .  influenzae and 
macrolide resistance among pneumococci. This repre- 
sents a major challenge to find new antimicrobial 
agents and new methods of overcoming resistance 
mechanisms. These strategies necessitate the use of 
alternative drugs, and the newer macrolides and fluoro- 
quinolones will be increasingly useful in the treatment 
of respiratory tract infections. 
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